siRNA Inhibition of DNA Methylation in Mycobacterium tuberculosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mycobacterium tuberculosis (TB) infections remain challenging due to multi-drug resistance and the rapid adaptation of the pathogen to drug treatments, with existing treatments being ineffective and grueling, and the mechanisms behind this adaptation are not fully understood, particularly regarding DNA methylation which is a scarcely explored alternative mechanism for phenotypic variation.
Innovation Solution
The use of DNA methylation inhibitory molecules, such as siRNA oligonucleotides targeting specific DNA methyltransferases like MamA, MamB, and HsdM, to inhibit DNA methylation in Mycobacterium tuberculosis, formulated in various pharmaceutical compositions for administration, potentially disrupting the pathogen's ability to adapt and persist.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TB drugs are used to treat Mycobacterium tuberculosis infection, then treatment is provided, but the pathogen rapidly adapts and develops multi-drug resistance making treatment ineffective
Solution Approach 1:
The patent extracts and targets the specific epigenetic mechanism (DNA methylation) that enables pathogen adaptation. By using siRNA molecules that specifically bind to and inhibit DNA methyltransferases (MamA, MamB, HsdM), the invention removes the adaptive capability without affecting the pathogen's essential survival functions, thereby preventing resistance development while maintaining treatment effectiveness
Solution Approach 2:
The invention changes the epigenetic parameters of the pathogen by inhibiting DNA methylation. The siRNA molecules alter the methylation status of specific genes, thereby changing gene expression patterns and preventing the phenotypic variations that lead to drug resistance. This parameter change disrupts the adaptation mechanism while allowing continued effective treatment
2Productivity
If current TB treatment regimens are administered, then patients receive therapy, but the treatment is grueling and has low success rate (52% success)
Solution Approach 1:
The patent employs preliminary action by using siRNA molecules that preemptively inhibit DNA methylation before the pathogen can adapt to standard treatments. By blocking the epigenetic modification pathways in advance, the treatment prevents the development of resistance mechanisms, thereby improving success rates and potentially shortening treatment duration by eliminating the need for prolonged multi-drug regimens
3Adaptability or versatility
If DNA methylation is inhibited in Mycobacterium tuberculosis, then adaptive mechanisms are disrupted, but the specific mechanism and targets need to be identified and targeted precisely
Solution Approach 1:
The patent segments the DNA methylation process into distinct targets by designing separate siRNA molecules for each DNA methyltransferase (MamA, MamB, HsdM). This segmentation allows precise targeting of individual enzymes involved in methylation, enabling selective inhibition of specific adaptive mechanisms without broadly affecting all epigenetic processes, thereby reducing complexity while maintaining effectiveness
Solution Approach 2:
The siRNA molecules serve as intermediaries that bridge the gap between the desired outcome (inhibiting pathogen adaptation) and the molecular target (DNA methyltransferases). These intermediary molecules specifically bind to the target enzymes and inhibit their function, providing a controlled and specific mechanism to disrupt adaptive processes without directly interacting with the pathogen's core structures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Inhibiting DNA methylation in TB bacteria could lead to more effective treatment options by disrupting the pathogen's adaptive mechanisms, potentially enhancing the efficacy of existing treatments and reducing resistance development.
Implementation Method 1
The use of DNA methylation inhibitory molecules, such as siRNA oligonucleotides targeting specific DNA methyltransferases like MamA, MamB, and HsdM, to inhibit DNA methylation in Mycobacterium tuberculosis
Implementation Method 2
DNA methylation is a plausible yet scarcely explored alternative mechanism for phenotypic variation in M. tuberculosis. M. tuberculosis encodes three known DNA methyltransferases (MTases), MamA, MamB, and HsdM
Data Source
AI summary
In alternative embodiments, provided are products of manufacture and kits, and methods, for treating or ameliorating a Mycobacterium tuberculosis (TB) or a Mycobacterium africanum infection. In alternative embodiments, provided are products of manufacture and kits, and methods, that comprise or comprise use of DNA methylation inhibitory molecules for treating or ameliorating a Mycobacterium tuberculosis (TB) infection. In alternative embodiments, provided are methods and device for classifying drug-resistance phenotype, or diagnosing Multi-drug resistant Tuberculosis (MDR-TB), eXtensively Drug Resistant phenotype (XDR) tuberculosis, or for clinical decision support. In alternative embodiments, provided are kits for or treating or diagnosing drug resistance of, prognosing, or assisting in clinical decision making for a Mycobacterium tuberculosis (TB) or the Mycobacterium africanum infection.